LIC HOUSING FINANCE LTD - RESULTS - FOR Q3 FY 2012-13 - QE DEC 2012 - TOTAL INCOME UP 23%; NET PROFIT DOWN 23% - FUTURE PROMISING

LIC Housing Finance Ltd

RESULTS FOR Q3 FY 2012-13

Q/E DEC,2012

Q3 net profit Rs 236.25 Cr

Q3 Loan Disbursements up by 27%

Outstanding Loan Portfolio up by 24%

Q3 Revenue from operations rises 24%

 LIC Housing Finance (LIC HFL) has announced its unaudited results for the third quarter ended December 31, 2012. The Board meeting was held in Mumbai on February 14, 2013.

Performance Highlights – Q3 FY2013

                                                  (Figures in Rs. crore)        

               Q 3 FY 13             Q 3 FY 12             Variation

Individual Loan Disbursals  ::  5508  ::  4568  ::  21%

Total Loan Disbursals      ::  6005  ::    4729  ::  27%

Revenue from operations  ::   1905   ::   1539   ::    24%

Total Income      ::   1955 ::   1593   ::  23%

Net Interest Income        ::  370    ::  326    ::  13%

Profit after Tax  ::   236.25   ::   305.69   ::   (23%)

Outstanding Loan Portfolio           ::   72704   ::    58707   ::  24%

                                                 

During third quarter ended December 31, 2012, the company disbursed loans worth Rs 6005 crores, registering a growth of 27% when compared to its performance during third quarter of the previous year. Out of the above, Individual loan disbursals grew 21% to Rs. 5508 crore.

The total income for the quarter was Rs 1955 crore as against Rs 1593 crore for the corresponding period of the previous year, recording a growth of 23%. Revenue from operations was Rs 1905 crore against Rs. 1539 crore for the corresponding period of the previous year, a growth of 24%.

Net Interest Income for the quarter was Rs 370 crore as against Rs 326 crore for the corresponding quarter of the previous year, a growth of 13%.

The Net profit for Q3 was Rs 236.25 crores when compared to Rs 305.69 crores in the corresponding period of the previous year.

Net interest margin of the Company for Q3 ended December 31, 2012 stood at 2.09% as against 2.10% for the Q2 ended September 30, 2012.

Performance Highlights – 9 months FY2013

  (Figures in Rs. crore)   

               9 M FY 13   :::    9M FY 12  ::  Variation

Individual Loan Disbursals  ::   15694 ::  12772        :: 23%

Total Loan Disbursals      ::  16634  ::  13415  ::  24%

Revenue from operations              ::  5431  ::  4355  ::  25%

Total Income      ::  5584  ::  4526  ::  23%

Net Interest Income        ::  1074  ::  1021  ::  5%

Profit after Tax  ::  707.05  ::  660.59   ::  7%

For the nine months ended December 31, 2012, LIC HFL disbursed loans worth Rs 16634 crore; registering a growth of 24%. Out of the total, Individual loan disbursals were Rs.    15694 crore, a growth of 23%.

The total income for the nine months ended December 31, 2012 was Rs 5584 crore as against Rs 4526 crore for the corresponding period of the previous year, recording a growth of 23%. Revenue from operations was Rs 5431 crore against Rs. 4355 crore for the corresponding period of the previous year, a growth of 25%.

The Net profit for the nine months ended December 31, 2012 was Rs 707.05 crore when compared to Rs 660.59 crore in the corresponding period of the previous year, registering a growth of 7%.

The outstanding loan portfolio of LIC HFL as on December 31, 2012 was Rs 72704 crore as against Rs 58707 crore as on December 31, 2011;  registering a growth of 24%.

The Gross NPA for the total portfolio stood at 0.74% as on December 31, 2012 and Net NPA was 0.45%.

LIC Housing Finance, Director & Chief Executive, Mr. V. K. Sharma, said “We have witnessed a healthy growth rate this quarter. It is very satisfying to mention that our recently launched home loan product for women ‘Bhagya Lakshmi’ has received an unprecedented response with over 3800 loan applications aggregating to nearly Rs 1000 cr with in a period of 3 weeks of the launch.”

Recent business developments:

•             LIC Housing Finance launched a new home loan product “Bhagyalakshmi” for women home seekers. Aimed at catering to the needs of a growing number of women home seekers, this product is available to women applicants who are the sole owner of the property or the first owner in a jointly owned property.

About LIC Housing Finance Ltd

LIC Housing Finance Ltd is one of the largest housing finance companies in India having one of the widest networks of offices across the country and representative offices at Dubai & Kuwait. In addition, the Company also distributes its products through branches of its subsidiary LICHFL Financial Services Ltd. LIC Housing Finance Ltd was promoted by Life Insurance Corporation in 1989 and a public issue was made in 1994.  It launched its maiden GDR offering in 2004. The company enjoys the highest rating from CRISIL & CARE indicating highest safety with regard to the ability to service interest and repay principal.

 *  *  *   E  N  D  *  *  *

Apollo Hospitals Enterprise Ltd - Results for Q3 FY 2012-13 - Q.E. DEC,2012 -

Apollo Hospitals Enterprise Ltd

Dr.Pratap. C.Reddy, Chairman

Dr.Preetha Reddy, MD

Results for Q3 FY 2012-13

Q.E. DEC,2012

Stand Alone Results

Apollo Hospitals Enterprise Ltd has declared its results for the third quarter ended Dec, 2012. 

Net Sales for Q3 FY 13 stands at Rs.855.79 Cr; compared to Rs.836.32 Cr in  Q2 FY 13 (+ 2.33%); and Rs.714.75 Cr In Q3 FY 12 (+19.73%).

Total Expenditure for Q3 FY 13 stands at Rs.736.94 Cr; compared to Rs.719.32 Cr in  Q2 FY 13 (+2.45%); and Rs.620.63 Cr In Q3 FY 12 (+18.74%).

Profit before Interest, Dep. & Taxes for Q3 FY 13 stands at Rs.118.85 Cr; compared to Rs.117.00 Cr in  Q2 FY 13 (+1.58%); and Rs.94.12 Cr In Q3 FY 12 (+26.27%).

Cost of materials  for Q3 FY 13 stands at Rs.260.62 Cr; compared to Rs.213.38 Cr in  Q2 FY 13 (+22.14%); and Rs.186.93 Cr In Q3 FY 12 (+39.42%).

Purchases of S-I-T        for Q3 FY 13 stands at Rs.222.23 Cr; compared to Rs.225.50 Cr in  Q2 FY 13 (-1.45%); and Rs.185.49 Cr In Q3 FY 12 (+19.81%).

Employee benefits for Q3 FY 13 stands at Rs.135.75 Cr; compared to Rs.130.49 Cr in  Q2 FY 13 (+4.03%); and Rs.108.60 Cr In Q3 FY 12 (+25%).

Depreciation expense for Q3 FY 13 stands at Rs.27.55  Cr; compared to Rs.26.99 Cr in  Q2 FY 13 (+2.07%); and Rs.24.25 Cr In Q3 FY 12 (+13.61%).

Other expenses for Q3 FY 13 stands at Rs.131.03 Cr; compared to Rs.126.60 Cr in  Q2 FY 13 (+3.5%); and Rs.114.56 Cr In Q3 FY 12 (+14.38%).

Total expenses for Q3 FY 13 stands at Rs.736.94 Cr; compared to Rs.719.32 Cr in  Q2 FY 13 (+2.45%); and Rs.  620.63   Cr In Q3 FY 12 (+18.74%).

Profit before tax for Q3 FY 13 stands at Rs.107.56 Cr; compared to Rs.112.53 Cr in  Q2 FY 13 (-4.42%); and Rs. 91.83 Cr In Q3 FY 12 (+17.13%).

Tax Expenses  for Q3 FY 13 stands at Rs.26.92   Cr; compared to Rs.29.29 Cr in  Q2 FY 13 (-8.09%); and Rs.27.18 Cr In Q3 FY 12 (-0.96%).

Net Profit  for Q3 FY 13 stands at Rs.80.64Cr; compared to Rs.83.24 Cr in  Q2 FY 13 (-3.12%); and Rs.64.65 Cr In Q3 FY 12 (+24.73%).The YoY Growth in respect of net Sales and net Profit is  impressive.

Face Value for Q3 FY 13 stands at Rs.5 and the Paid-up Equity stands at Rs.69.56 Cr.

              

Basic EPS  for Q3 FY 13 stands at Rs.5.8; compared to Rs.6.02 in Q2 FY 13; and Rs.4.89 in Q3 FY 12

              

Public holding in the company is 61.93%.

EXCERPTS FROM THE COMPANY’S RELEASE

Apollo Hospitals announced Q3 FY13 results Strong Quarter with Well-rounded Performance. World’s #1Transplant Hospital Group with more than 1200 solid organ transplants for the year 2012, Apollo Specialty Hospital, Chennai successfully completed 500 Bone Marrow Transplants; Announces Establishment of the first Proton Therapy center for Cancer treatment in Chennai 

consolidated financial results for the quarter and nine months ended December 31, 2012.

Q3 FY13 Consolidated  Revenues up 22.2 % at Rs.9,809 million 

Consolidated EBITDA up 18.9% at Rs.1,587 million

Consolidated PAT up 22.2% at Rs.746 million 

Q3 FY13 Standalone Revenues up 19.7% at Rs.8,558  million 

Standalone EBITDA up 20.5% at Rs.1,464 million

Standalone PAT up 24.7 % at Rs.806 million

Commenting on the performance, Dr. Prathap C Reddy, Chairman said, “We are pleased to report continued growth and operating improvements in Q3 driven by sustained focus on clinical excellence. We continue to pioneer the introduction of technology based treatment in India with our plan to set up the first ever Proton Therapy Center in the region at Chennai. This new facility will offer patients across Asia, Africa and Australia the most advanced radiation therapy technology and enhance Apollo Hospitals’ ability to provide superior cancer treatment.

He added , “The improving performance of our pharmacies business is contributing to balanced growth. The sale of our stake in Apollo Health Street has also strengthened our balance sheet as we are embarking on a never before expansion plan with 14 hospitals scheduled to be added to our network over the next 30 months .”

Financial Highlights

• Standalone Q3FY13 Performance

O Revenues grew 19.7% to Rs.8,558 million compared to Rs.7,148million in Q3 FY12.

O EBITDA grew 20.5% to Rs.1,464 million as against Rs.1,215 million in Q3 FY12.

O PAT was Rs.806 million vs. Rs.647 million in Q3 FY12, growth of 24.7%.

O Diluted EPS of Rs.5.80 per share in Q3 FY13 (not annualised)

• Standalone 9M FY13 Performance

O Revenues grew 20.1 % to Rs.24,695 million compared to Rs.20,555 million in 9M FY12.

O EBITDA grew 22.2 % to Rs. 4,208 million as against Rs.3,444 million in 9M FY12.

O PAT was Rs.2,336 million in 9M FY13 vs. Rs.1,717 million in 9M FY12.

O Diluted EPS of Rs. 16.79 per share in 9M FY13 

• Consolidated Q3 FY13 Performance*#

O Revenues grew 22.2% to Rs.9,809 million compared to Rs.8,029 million in Q3 FY12.

O EBITDA grew 18.9 % to Rs.1,587 million as against Rs.1,335 million in Q3 FY12.

O PAT was Rs.746 million vs. Rs.610 million in Q 3 FY12, growth of 22.2%.

O Diluted EPS of Rs.5.36 per share in Q3 FY13 (not annualised)

• Consolidated 9M FY13 Performance*#

O Revenues grew 22.2% to Rs.28,242 million compared to Rs.23,111 million in 9M FY12.

O EBITDA grew 22.8% to Rs.4,687 million as against Rs.3,815 million in 9M FY12.

O PAT was Rs.2,351 million in 9M FY13 vs. Rs.1,741 million in 9M FY12.

O Diluted EPS of Rs.16.90 per share in 9M FY13

* The Consolidated financials are unaudited management estimates

# Apollo Health Street financials have not been considered in the consolidated financials after the Share Purchase agreement for the divestiture has been signed with Sutherland.

Operating Highlights

• Standalone Pharmacies continued to report stellar growth –Q 3 revenues grew 29.3% on a y-on-y basis to Rs.2,905 million – aided by robust same store sales growth, focus on private labels and renewed momentum in expansion of the pan - India network of stores.

• Apollo Hospitals has signed a definitive agreement with Sutherland Global Services (SGS) under which SGS will acquire a 100% stake in Apollo Health Street(AHS). The listed entity, AHEL, holds a 39% stake in AHS; the balance being held by promoters, Institutional Investors & Minority Shareholders. The deal is expected to close in Feb 2013 subject to regulatory and other conditions.

• Apollo Hospitals has announced plans to establish a Proton Therapy Center in Chennai. The center, with an approximate investment of Rs. 400 crores, is designed with state – of -the-art technology, Proteus®PLUS from IBA (Ion Beam Applications S.A.) to provide best -in-class treatment for cancer treatment.

Awards & Achievements

• Apollo Hospitals was voted the No. 1 private hospital in India (Week–HANSA Best Hospital Survey, 2012).

• Apollo Hospitals bagged the ‘Asia Responsible Entrepreneurship Awards’ (AREA) South Asia 2012 under two categories organized by Enterprise Asia on 13th December in New Delhi. Group Chairman, Dr. Prathap Reddy won the prestigious Responsible Business Leader Category and Billion Hearts Beating Foundation won the praiseworthy  Health Promotion Award.

• Indraprastha Apollo Hospitals won the “Times Research Media Healthcare Excellence Awards 2012” on 26th December 2012, in three categories - India's most innovative hospital, best diagnostic and imaging centre in North India and best heart care centre in North India.

About Apollo Hospitals Enterprise Ltd. (AHEL)

It was in 1983, that Dr. Prathap Reddy made a pioneering endeavour by launching India’s first corporate hospital - Apollo Hospital in Chennai. Now, as Asia largest and most trusted healthcare group, its presence includes over 8,020 Beds across 49 Hospitals, 1,445 Pharmacies, 100 primary care and diagnostic Clinics, 100 Telemedicine units across 10 countries (added Burma in Q3).

Health Insurance services, Global Projects Consultancy, 15 colleges of Nursing and Hospital Management and a Research Foundation with a focus on global Clinical Trials, epidemiological studies, stem cell & genetic research and the first Proton Therapy Center across Asia, Africa and Australia .

In a rare honor , the Government of India issued a commemorative stamp in recognition of Apollo's contribution, the first for a healthcare organization. Apollo Hospitals Chairman, Dr. Prathap C Reddy, was conferred with the prestigious Padma Vibhushan in 2010. For more than 30 years, the Apollo Hospitals Group has continuously excelled and maintained leadership in medical innovation, world - class clinical services and cutting - edge technology. Our hospitals are consistently ranked amongst the best hospitals globally for advanced medical services and research.

 *  *  *  E  N  D  *  *  *

VENUS REMEDIES LTD - RESULTS FOR - Q3 FY 2012-13 - Q.E DEC 2012 - NET SALES UP 18.62%; NET PROFIT UP 55.47% YoY

VENUS REMEDIES LTD

Venus Remedies has declared its results for the third Quarter ends December, 2012.

The results are analyzed below :

Net Sales for the 3^rd Quarter stands at Rs.111.62 Cr; compared to Rs.110.66 cr  in the Q2 FY 13 (+0.87%); and  Rs.94.1Cr in Q3 FY 12 (+18.62%).

Total Income for the 3^rd Qtr stands at Rs.112.64 Cr compared to Rs.110.81 Cr in Q2 FY 12 (+ 1.65%); and Rs.95.83 Cr in Q3 FY 12 (+ 17.54%). The improvement in Net Sales and total income on YoY basis is very good.

Total Expenses for the 3^rd Qtr stands at Rs.90.74 Cr compared to Rs.90   Cr in Q2 FY 12 (+ 0.82%); and Rs.78.21 Cr in Q3 FY 12 (+16.02%). The rise in expenses is lower, compared to Income.

Operating Profit for the 3^rd Qtr stands at Rs.21.89 Cr compared to Rs.20.81 Cr in Q2 FY 12 (+ 5.19%); and Rs.17.62 Cr in Q3 FY 12 (+24.23%). Operating Profit has gone up impressively

Finance Costs     for the 3^rd Qtr stands at Rs.5.29   Cr compared to Rs.5.37  Cr in Q2 FY 12 (-1.49%); and Rs.6.68 Cr in Q3 FY 12 (-20.81%).

Tax Expense    for the 3^rd Qtr stands at Rs.0.9     Cr;  compared to Rs.0.6  Cr in Q2 FY 12 (+ 50%); and Rs.0.7 Cr in Q3 FY 12 (+28.57%).

Net Profit for the 3^rd Qtr stands at Rs.16.06 Cr;  compared to Rs.15.09 Cr in Q2 FY 12 (+ 6.43%) and Rs.10.33 Cr in Q3 FY 12 ( +55.47%).Net Profit YoY has jumped impressively due to higher sales (+18.62%) and proportionately lower total expenses (+16.02%) and lower fiancé costs (-20.81%).

Equity   stands at Rs.9.742

EPS for the 3^rd Qtr stands at Rs.16.48  compared to Rs.15.49 in Q2 FY 13; and Rs.10.33 in Q3 FY 12.

EPS-Annualised for the 3^rd Qtr stands at Rs.65.92 compared to Rs.61.97    in the second Qtr and Rs.45.21 in Q3 FY 12. 

     

9 MONTHE ENDED DEC,2012

Net Sales for the 9 m/e Dec,2012 stands at Rs.334.9 Cr; compared to Rs.289.1 cr (+15.84%); while the same for the full Year ended March 2012 stands at Rs.402.39 Cr.

Total Income   for the 9 m/e Dec,2012 stands at Rs.336.02 Cr; compared to Rs.290.95 cr (+15.49%); while the same for the full Year ended March 2012 stands at Rs.    405.19 Cr.

Total Expenses for the 9 m/e Dec,2012 stands at Rs.271.4 Cr; compared to Rs.232.6 cr (+16.68%); while the same for the full Year ended March 2012 stands at Rs.323.15 Cr.

Operating Profit for the 9 m/e Dec,2012 stands at Rs.64.66 Cr; compared to Rs.58.32 cr (+10.87%); while the same for the full Year ended March 2012 stands at Rs.82.04 Cr.

Finance Costs  for the 9 m/e Dec,2012 stands at Rs.18.28 Cr; compared to Rs.18.64 cr (-1.93%); while the same for the full Year ended March 2012 stands at Rs.27.26 Cr.

Tax Expense    for the 9 m/e Dec,2012 stands at Rs.1.9   Cr; compared to Rs.4.15 cr (-54.22%); while the same for the full Year ended March 2012 stands at Rs.5.12 Cr.

Net Profit for the 9 m/e Dec,2012 stands at Rs.45.19 Cr; compared to Rs.35.71 cr (+26.55%); while the same for the full Year ended March 2012 stands at Rs.50.03 Cr. The jump on YoY basis is quite good.

EPS for the 9 m/e Dec,2012 stands at Rs.45.19; compared to Rs.35.71  (+26.55%); while the same for the full Year ended March 2012 stands at Rs.50.03 .

EPS-Annualised for the 9 m/e Dec,2012 stands at Rs.61.85; compared to Rs.52.08 (+18.76%); while the same for the full Year ended March 2012 stands at Rs.51.35.

The performance of the company for the third quarter and for the 9 months ending Dec,2012 is quite impressive. It has been improving its performance steadily every quarter. The stock price has jumped almost Rs.30.50 on declaration of results - to Rs.277.95. Even at this price, its PE Ratio is hardly 4.1 - leaving huge scope for appreciation.

*   *   *   E  N  D  *  *  *